Skip to main content
European Commission logo print header
Contenido archivado el 2022-12-23

Design, synthesis, structure, antitumour activity and DNA binding of new platinum compounds

Objetivo



For a better understanding and improved clinical use of the antitumour drugs cisplatin and carboplatin detailed studies of the DNA binding are highly important. Given the narrow range of tumours that can be treated by these compounds, and given their severe toxic side effects, a desperate need exists for the development of totally new Pt compounds. The major objective of this joint research is to design and synthesize novel Pt compounds with improved antitumour properties. The new compounds will be structurally characterized, and checked for antitumour properties and for binding to nucleic acids. Special attention will be given to a study of the mechanism of the antitumour properties of the newly synthesized platinum compounds.

The research will consist of: the design and synthesis of new Pt compounds; the study of their biological properties; the binding of the compounds to small synthetic fragments of nucleic acids and their precise structures; and the binding to DNA and RNA from several sources and the structural changes occurring as a result of metal binding.

Convocatoria de propuestas

Data not available

Régimen de financiación

Data not available

Coordinador

Rijksuniversiteit Leiden
Aportación de la UE
Sin datos
Dirección
Einsteinweg 55
2333 CC Leiden
Países Bajos

Ver en el mapa

Coste total
Sin datos

Participantes (3)